High-quality raw materials and ancillary reagents are needed for ex vivo cell manufacturing processes. We have a best solution for that.
Unparalleled Combination of Protein and Regulatory Experience
• Our partner, R&D Systems, a Bio-Techne brand, has been developing and manufacturing proteins since 1985.
• They have the capacity and the scientific expertise to support the large -scale production of GMPgrade proteins.
• R&D Systems GMP-grade proteins are being used in numerous clinical trials.
• They welcome client audits of their facilities.
• If specific GMP-grade raw materials are not currently available, our team will work with you to develop the products that you need.
• We assure your confidentiality.
• R&D Systems has more than 100 protein scientists dedicated to development and manufacturing.
• They have more than 90
employees in quality and regulatory roles.
We offer an expanding line of Avi-tag biotinylated proteins, QC tested for equivalent bioactivity and lot-to-lot consistency.
Advantages of Avi-tag Biotinylated Recombinant Proteins
• Consistent labelling. Biotinylation only occurs on the single lysine residue in the Avi-tag.
• Uniform orientation of protein. When bound to a streptavidin-coated surface, the avi-tagged protein orientation will be uniform due to the precise control over biotinylation.
• Equivalent bioactivity. Because biotinylation is restricted to the Avi-tag, the rest of the protein is unchanged so there is no interference in the protein’s bioactivity.
We have some of the current and emerging immune checkpoint molecules that are being investigated as potential targets for cancer immunotherapy.
Regulators of the immune checkpoint represent some of the most promising targets for immunotherapy. We offer the widest selection of checkpoint proteins, all assessed for bioactivity and held to rigorous specifications that must be matched for each lot of protein made. The proteins include a selection of different tags and species, including Cynomolgus, allowing for maximum experimental flexibility.
eBook: Current and emerging Immune Checkpoint targets for Immuno-oncology Research.